……as new drug that could dramatically speed up the elimination the disease begins clinical trial.
By John Chola -1 July, 2009:
Over 100 million people are at risk of infection with river blindness or onchocerciasis in Africa and a few small areas in the Americas and Yemen.
And a clinical trial is being launched in three African countries of a drug that could eliminate river blindness.
Onchocerciasis or river blindness is currently one of the leading infectious causes of blindness in Zambia and across Africa.
The drug, moxidectin, is being investigated for its potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis.
Director of the African Programme for Onchocerciasis Control (APOC) Dr Uche Amazigo says river blindness is a devastating illness that has plagued Zambia and other 29 African countries for centuries.
Dr Uche Amazigo says populations in the most remote areas are the most affected.
Dr Amazigo explains that Onchocerciasis is also called river blindness because the blackfly which transmits the disease breeds in fast flowing rivers, and blindness is the most incapacitating symptom of the disease which also causes debilitating skin disease.
Dr Amazigo says the development of moxidectin for onchocerciasis is being conducted through a collaboration of the Special Programme for Research and Training in Tropical Diseases, which is executed by the World Health Organization (WHO/TDR), and Wyeth Pharmaceuticals.
The work ranges from the development of a formulation for human use and initial studies in healthy volunteers, to clinical studies and community studies in Africa.
WHO/TDR, working in partnership with African investigators and institutions, is building the capacity and managing the conduct of the clinical trials conducted in Africa.
If the development is successful and results in a positive scientific opinion from the European Medicines Evaluation Agency, Wyeth, with the assistance of WHO, will request approval by national regulatory authorities in the countries such as Zambia where onchocerciasis is endemic.
Dr Henrietta Ukwu, Vice President, Wyeth Pharmaceuticals, said his company is committed to improving access to innovative drugs and biologics around the globe including in the developing world.
Dr Ukwu said the moxidectin data have been promising so far, and as the programme moves into larger phase III (3) studies, they are hopeful that moxidectin will constitute a significant advance against this devastating disease.
In conducting this trial, TDR will be working with African investigators and institutions.
Fifteen hundred people at 4 sites in Ghana, Liberia and the Democratic Republic of Congo will be enrolled in the study.
Preparation has been ongoing since 2007, and included building a clinical research centre in Lofa County, Liberia, and in North-Kivu in the Democratic Republic of Congo (DRC).
Buildings not used since the war in Ituri, DRC, have been renovated while all centers have been provided with necessary equipment and the research teams trained on how to conduct the trial according to international standards.
The trial will take place over the next two and a half years.
Currently, the disease is controlled by ivermectin, which has been donated for more than 20 years by the pharmaceutical company Merck & Co., Inc., for use in onchocerciasis endemic countries.
Treatment with ivermectin has enabled significant progress in the control of onchocerciasis, and currently reaches more than 60 million people in Africa annually.
However, ivermectin kills the O. volvulus larvae but not the adult worms.
This makes annual treatments for an extended period of time of between 11 to 14 years are required to ensure disease control.
If moxidectin kills not only the larvae but also sterilizes or kills the adult worms, it has the potential to interrupt the disease transmission cycle within around 6 annual rounds of treatment.
The drug could be distributed through the community-directed mechanisms set up in collaboration among APOC, African control programmes, and NGOs for the distribution of ivermectin.
Ends.
